{"id":"NCT02269488","sponsor":"AstraZeneca","briefTitle":"A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years","officialTitle":"A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11","primaryCompletion":"2015-02","completion":"2015-02","firstPosted":"2014-10-21","resultsPosted":"2015-09-28","lastUpdate":"2015-09-28"},"enrollment":100,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Healthy Japanese Children Age 2 Years Through 6 Years"],"interventions":[{"type":"DRUG","name":"MEDI3250","otherNames":[]}],"arms":[{"label":"MEDI3250","type":"EXPERIMENTAL"}],"summary":"This open-label, single arm, multicenter study will enroll approximately 100 subjects. The study is designed to gather the safety and tolerability data in Japanese children 2 to 6 years of age that would support approval of MEDI3250 in Japan.","primaryOutcome":{"measure":"Number of Participants With Solicited Symptoms Experienced From Administration of MEDI3250","timeFrame":"14 days post vaccination","effectByArm":[{"arm":"MEDI3250","deltaMin":57,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":["Nasopharyngitis"]}}